Cargando…
Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes
The sodium‐glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduces heart failure in diabetes, but underlying mechanisms remain elusive. We hypothesized that empagliflozin could counteract the senescence of cardiac stromal cells (CSC), the action of which limits cardiac damage and cardiac fib...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687009/ https://www.ncbi.nlm.nih.gov/pubmed/32940423 http://dx.doi.org/10.1111/jcmm.15699 |